News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
898,069 Results
Type
Article (89674)
Company Profile (639)
Press Release (807732)
Multimedia
Podcasts (283)
Webinars (44)
Section
Business (267510)
Career Advice (4176)
Deals (40162)
Drug Delivery (246)
Drug Development (92150)
Employer Resources (212)
FDA (18737)
Job Trends (17562)
News (399631)
Policy (40038)
Tag
2025 Best Places to Work (25)
2026 Best Places to Work (39)
2027 BioCapital Standard (5)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (13)
2027 Biotech Beach Digital (1)
2027 Biotech Beach Standard (7)
2027 Genetown Elite (2)
2027 Genetown Standard (6)
2027 NextGen (10)
2027 Pharm Country Digital (4)
2027 Pharm Country Premier (1)
2027 Pharm Country Standard (5)
40 Under 40 (4)
Academia (3112)
Academic (2)
Accelerated approval (76)
ADA (54)
Adcomms (44)
Allergies (237)
Alliances (57000)
ALS (292)
Alzheimer's disease (2143)
Antibody-drug conjugate (ADC) (776)
Approvals (19330)
Artificial intelligence (1147)
ASCO (350)
Autoimmune disease (536)
Automation (84)
Bankruptcy (414)
Belgium (45)
Best Places to Work (12636)
BIO (84)
Biologics (117)
BIOSECURE Act (23)
Biosimilars (307)
BioSpace Insights (271)
Biotechnology (340)
Bispecific (60)
Bladder cancer (253)
Brain cancer (104)
Breast cancer (976)
Cancer (8052)
Cardiovascular disease (684)
Career advice (3638)
Career pathing (65)
CAR-T (465)
CDC (82)
CDMO (236)
Celiac Disease (7)
Cell-line development (2)
Cell therapy (1278)
Cervical cancer (67)
Clinical research (81235)
Collaboration (2887)
Commercialization (76)
Company closure (10)
Compensation (1936)
Complete response letters (128)
COVID-19 (3088)
CRISPR (155)
CRO (8)
C-suite (1712)
Cystic fibrosis (182)
Data (11162)
Decentralized trials (4)
Denatured (112)
Depression (230)
Dermatology (207)
Diabetes (853)
Diagnostics (7944)
Digital health (85)
Diversity (14)
Diversity, equity & inclusion (49)
Drug discovery (565)
Drug pricing (255)
Drug shortages (41)
Duchenne muscular dystrophy (388)
Earnings (104788)
Editorial (85)
Employer branding (27)
Employer resources (184)
ESMO (441)
Events (141975)
Executive appointments (1385)
Eye disease (27)
FDA (23860)
Fibrodysplasia Ossificans Progressiva (17)
Fragile X (6)
Friedreich's ataxia (29)
Frontotemporal dementia (42)
Funding (2378)
Gene editing (323)
Generative AI (116)
Gene therapy (988)
GLP-1 (1416)
Government (5635)
Grass and pollen (8)
Guidances (446)
Healthcare (21521)
Hematology (236)
HIV (128)
Huntington's disease (93)
Idiopathic pulmonary fibrosis (16)
IgA nephropathy (155)
Immunology and inflammation (431)
Immuno-oncology (166)
Indications (298)
Infectious disease (3550)
Inflammatory bowel disease (285)
Inflation Reduction Act (17)
Influenza (168)
Intellectual property (388)
Interviews (830)
IPO (18071)
IRA (61)
Job creations (5211)
Job search strategy (2882)
JPM (73)
Kidney cancer (31)
Kidney disease (181)
Labor market (152)
Layoffs (733)
Leadership (70)
Legal (10180)
Licensing (127)
Liver cancer (121)
Longevity (58)
Lung cancer (1109)
Lung diease (27)
Lymphoma (565)
Machine learning (78)
Management (72)
Manufacturing (1659)
Marketing (41)
MASH (260)
Medical affairs (5)
Medical device (15485)
Medtech (15821)
Mergers & acquisitions (23648)
Metabolic disorders (2172)
Middle East (2)
mRNA (344)
Multiple sclerosis (262)
Multispecific (6)
NASH (24)
Netherlands (40)
Neurodegenerative disease (635)
Neuropsychiatric disorders (155)
Neuroscience (4358)
Neurotech (4)
NextGen: Class of 2026 (7718)
Non-profit (5175)
Now hiring (101)
Obesity (1027)
Opinion (410)
Ovarian cancer (301)
Pain (352)
Pancreatic cancer (458)
Parkinson's disease (495)
Partnered (53)
Patents (814)
Patient advocacy (8)
Patient recruitment (988)
Patient selection (117)
Peanut (81)
People (69162)
Peptides (44)
Pharmaceutical (83)
Pharmacy benefit managers (43)
Phase 1 (25052)
Phase 2 (35285)
Phase 3 (26598)
Pipeline (14640)
Policy (435)
Postmarket research (3561)
Preclinical (11209)
Press Release (74)
Prostate cancer (413)
Psychedelics (104)
Radioligand (3)
Radiopharmaceuticals (449)
Rare diseases (1613)
Real estate (7479)
Recruiting (84)
Regenerative medicine (38)
Regulatory (31896)
Reports (104)
Research institute (2823)
Resumes & cover letters (657)
Rett syndrome (59)
RNA editing (39)
RSV (107)
Saudi Arabia (1)
Schizophrenia (230)
Series A (410)
Series B (285)
Service/supplier (17)
Sickle cell disease (152)
Special edition (38)
Spinal muscular atrophy (201)
Sponsored (61)
Startups (4405)
State (2)
Stem cells (8)
Stomach cancer (24)
Substance use disorders (23)
Supply chain (172)
Switzerland (24)
Tariffs (108)
Tax incentives (2)
The Weekly (168)
Vaccines (1447)
Venture capital (185)
Weight loss (682)
Wet AMD (7)
Women's health (190)
Women in leadership (1)
Worklife (28)
Date
Today (233)
Last 7 days (976)
Last 30 days (3940)
Last 365 days (34032)
2026 (30698)
2025 (33214)
2024 (37866)
2023 (42564)
2022 (53927)
2021 (58720)
2020 (57662)
2019 (51334)
2018 (39119)
2017 (37186)
2016 (38329)
2015 (44431)
2014 (39672)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1310)
Alabama (118)
Alaska (7)
Arizona (493)
Arkansas (17)
Asia (53203)
Australia (9370)
California (17352)
Canada (4777)
China (2069)
Colorado (769)
Connecticut (775)
Delaware (546)
Europe (122854)
Florida (2630)
Georgia (566)
Hawaii (5)
Idaho (70)
Illinois (1502)
India (155)
Indiana (786)
Iowa (37)
Japan (779)
Kansas (159)
Kentucky (69)
Louisiana (73)
Maine (99)
Maryland (2045)
Massachusetts (12555)
Michigan (475)
Minnesota (954)
Mississippi (8)
Missouri (189)
Montana (38)
Nebraska (31)
Nevada (204)
New Hampshire (94)
New Jersey (4595)
New Mexico (38)
New York (4523)
North Carolina (2250)
North Dakota (14)
Northern California (8865)
Ohio (542)
Oklahoma (32)
Oregon (55)
Pennsylvania (3323)
Puerto Rico (38)
Rhode Island (66)
South America (1674)
South Carolina (104)
South Dakota (2)
Southern California (6911)
Tennessee (285)
Texas (2889)
United States (61511)
Utah (527)
Vermont (2)
Virginia (436)
Washington D.C. (89)
Washington State (1385)
West Virginia (4)
Wisconsin (200)
Wyoming (6)
898,069 Results for "ela medical s a s".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mergers & acquisitions
Lilly’s early-stage M&A quest finds $1.5B deal for Calytrix’s blood cancer work
Eli Lilly’s business development team has inked 14 buyouts this year so far, with Calytrix Bio tucking into the pharma’s oncology pipeline.
November 16, 2026
·
1 min read
·
Annalee Armstrong
Press Releases
Electra Therapeutics Announces Initiation of a Phase 1 Trial of ELA822, a Novel SIRPγ-Specific Antibody Designed to Treat T Cell-Mediated Immune and Inflammatory Diseases
September 10, 2026
·
3 min read
Business
Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more
New data for Genmab and AbbVie’s bispecific antibody Epkinly wowed analysts and could set the partners up for an expanded approval in diffuse large B cell lymphoma; deals have flowed steadily this week, including Novartis’ nearly $8 billion bet on mRNA drugs with China’s Abogen Biosciences; and could Sarepta Therapeutics turn things around from last year’s annus horribilis?
October 7, 2026
·
2 min read
·
Jef Akst
Diabetes
Lilly’s retatrutide trounces Novo’s Ozempic in diabetes, weight loss
Eli Lilly’s next-gen weight loss drug retatrutide soundly beat Novo’s approved medicine Ozempic in weight loss and blood sugar reduction, padding the case for a regulatory application that’s expected in the first quarter of 2027.
October 28, 2026
·
3 min read
·
Annalee Armstrong
China
China’s licensing deals soar as US biotechs enjoy a bumper M&A year
China may be taking the majority of licensing deals this year but those transactions don’t tell the whole story, according to Locust Walk, which points to the spike in M&A among U.S. biotechs as leveling the playing field.
October 21, 2026
·
3 min read
·
Annalee Armstrong
Podcast
Disc’s redemption, China’s rise, Veradermics’ validation, ESMO’s headliners
China cracks down on some biotechnology ownership transfers—but will the new policy impact licensing deals?; Disc Medicine’s Phase 3 data sweep redeems rejected rare disease therapy, teeing up another FDA run; and the ESMO conference gets underway in Madrid this week, with much-anticipated data from Merck, and Summit Therapeutics.
October 21, 2026
·
1 min read
·
Jef Akst
China
Without US action on China’s innovation blitz, biotech leaders see a Rust Belt future
Policy uncertainty is hampering the growth of U.S. biotech as China rises thanks to carefully planned investment in the industry, experts said during a
BioSpace
webinar.
November 11, 2026
·
5 min read
·
Annalee Armstrong
Venture capital
Alphabet’s GV is one of biotech’s most influential corporate investors
The corporate investor arms of Eli Lilly, Sanofi and Pfizer have participated in billions worth of venture capital rounds, but GV is the industry’s biggest spender.
October 27, 2026
·
2 min read
·
Annalee Armstrong
Drug Development
Sanofi’s axing of Nurix STAT6 program ‘not a target-related issue’
Sanofi has discontinued an early-stage STAT6 degrader program licensed from Nurix Therapeutics, a decision analysts say is related to the asset itself or Sanofi’s strategic reprioritization rather than the drug class more broadly.
November 4, 2026
·
3 min read
·
Heather McKenzie
Eye disease
Merck’s experimental eye drug matches Roche’s VEGF inhibitor but safety concerns emerge
Analysts were keen to see a new modality compete with Roche’s approved drug Lucentis in the late-stage trial but new safety issues could complicate the future for Merck’s candidate.
September 24, 2026
·
2 min read
·
Annalee Armstrong
1 of 89,807
Next